RSK is a highly sought-after drug target for breast cancer and, more recently prostate cancer.

Click on the timeline below to access highlights of key opinion leaders and our work validating the role of RSK in cancer.

Posters & Abstracts

“High levels of RSK2 in breast cancer patients is associated with longer PFS in patients treated with PMD-026, a first in class RSK inhibitor”, Wang et al., SABCS 2022

“PMD-026, a First in Class Oral RSK inhibitor, Demonstrates Activity Against Hormone Receptor Positive Breast Cancer with Acquired CDK4/6 Inhibitor Resistance”, Jayanthan et al., AACR 2022

“First-in-human phase 1/1b expansion of PMD-026, an oral RSK inhibitor, in patients with metastatic triple negative breast cancer”, Beeram et al., ASCO 2021

'‘First-in-Human Expansion Study of Oral PMD-026 in Metastatic Triple Negative Breast Cancer Patients”, Beeram et al., SABCS 2021

“PMD-026, a First in Class Oral RSK inhibitor, Demonstrates Synergy When Combined with Standard of Care in Breast Cancer Tumor Models”, Jayanthan et al., AACR 2021

“Targeting B-Raf and Checkpoint Inhibitor Resistant Melanoma with RSK inhibitor PMD-026”, Ramos et al., AACR 2021

“A first-in-human Phase 1/1b multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026, a first-in-class oral RSK inhibitor, in metastatic breast cancer patients”, Beeram et al., SABCS 2020

“A First in Class RSK Kinase Inhibitor, PMD-026, Demonstrates Activity in Inflammatory Breast Cancer”, Jayanthan et al., MD Anderson IBC Education Day 2020

“First-in-human phase I/Ib multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026 in patients with metastatic breast cancer with expansion in metastatic triple negative breast cancer”, Beeram et al., ASCO 2020

“PMD-026, a first-in-class oral p90 ribosomal S6 kinase (RSK) inhibitor for triple negative breast cancer (TNBC)”, Dunn et al., SABCS 2019